U.S. stock futures are edging mostly higher as investors watch corporate earnings, Honeywell plans to split into three companies, and Qualcomm stock drops as its licensing revenue misses expectations.

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

Farley also defended Ford’s U.S. manufacturing footprint, pointing out that about 80% of Ford vehicles sold in the U.S. are ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

A number of factors - chiefly, the bird flu - is causing you to pay more for eggs at the market than ever. Will the price of ...

President Donald Trump is flirting with a poison pill that would ruin his America First, MAGA agenda. Tuesday evening, Trump ...

GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...

Lisata Therapeutics (NASDAQ:LSTA) lost ~38% in the premarket on Wednesday after the cancer drug developer shared results from a mid-stage trial for its main asset, certepetide, in patients with ...

Decided to add this retail giant to your portfolio? Here's what you need to know before buying Amazon stock. Many, or all, of the products featured on this page are from our advertising partners ...

Speaking at a panel in Davos on Tuesday, Hudson said Sanofi uses AI to recommend whether drugs should "pass through a tollgate," or essentially get approval to move to the next phase of development.